Motilent

Motilent’s EntrolyticsMD is now ready for clinical use in the United States. EntrolyticsMD, the world's first imaging platform for digestive diseases has been listed with the FDA. 40 Million people are affected by digestive diseases (including inflammatory bowel disease and GI cancers) costing $119.6 billion in 2018. EntrolyticsMD is already in use across over 300 investigator projects, for AI deployment and in clinical trials.

Are you involved in caring for IBD patients in the UK? 👇 #IBD #gastroenterology #radiology #NHS #IUS #bowelultrasound

Where to catch Motilent in October ✈️ UEG - United European Gastroenterology & American College of Gastroenterology! Head to the comments to book in a meeting with the team 👇 #UEGweek #ACG #ACGfamily #weareUEG #myUEGcommunity

Issue 12 of The Motilent Monthly Digest is out! 📧 ✈️ Motilent on the road: 5 conferences down 3 to go... ☀️ Busy summer: A breakdown of our top 3 of 21 abstracts! 🤔 “We should scrap the name Gastroparesis”: Alex Menys shared his thoughts Click here to read more: https://lnkd.in/eze3FFzj

We're looking for an experienced Senior Backend #SoftwareEngineer, who's eager to work at the forefront of clinical science and #research. If you're..... 👉 Passionate about solving some of medicine's toughest challenges 👉 Enjoy developing scalable #backend solutions using cutting-edge technologies We want to hear from you! This role offers you ownership, career growth, and the opportunity to continually expand your skills in a dynamic, mission-driven environment. Ready to make an impact? 👉 Click below! https://lnkd.in/e3vytV-f #hiring #medtechjobs #softwarejobs

Check out this post from FIBROTARGET highlighting recent research using our tools GIQuant and GISeg 👇 Click the link below to explore how these studies align with the #FIBROTARGET mission, to advance the prevention, diagnosis, and treatment of intestinal #fibrosis and fibrostenosis. #IBD #digestivediseases #Crohnsdisease

Where does Motilent overlap with Pharma? It's unsurprising to see an increasing number of #IBD and #Motility drugs making it onto the list of top 10 sold medicines -  let's take a look at the drugs in the IBD and GLP-1 space that made the cut…. Key players for IBD:  - AbbVie: Skyrizi and Rinvoq -Johnson & Johnson:  Stelara and Tremfya GLP-1’s treating #gastrointestinal conditions:  - Eli Lilly and Company: Mounjaro - Novo Nordisk Nordis: Ozempic For these drugs to get to market, the right drug needs to be tested on the right patient at the right time. #PatientStratification and #CohortEnrichment underpin successful #ClinicalTrials and lead to successful #clinicaldeployment. We will be keeping an eye out to see which drugs make the top 10 for Q3 and which drugs have clinical traction across areas in which Motilent is actively engaged. #IBD #gastroparesis #EoE #GIdiseases #GLP1 #crohnsdisease #crohns #UC #ulcerativecolitis A great post from Arjun Murthy 👇

📢 We are hiring! 2 great opportunities to join the team here at Motilent and take our products to the next level in international research, life-science and clinical markets 👇 👉 DevOps Engineer: https://lnkd.in/e3Be65pj 👉 Backend Software Engineer: https://lnkd.in/ev87ssAK

Let's talk standardisation of MRE Reporting in IBD. Everyone does the same thing right….? 😳👇 Apparently not! The burden of Inflammatory Bowel Disease (IBD) is rising with a prevalence of 1 in every 200-300 people in Europe and the US highlighted in a recent high-impact piece from the BBC News and Crohn's & Colitis UK. Standardising #MRI reports is essential for detecting complications, monitoring therapeutic response, and predicting long-term outcomes. In a recent study Luca Balzarini et al surveyed 253 radiologists across Italy in April 2023 on their experiences with Magnetic Resonance Enterography (MRE) in IBD cases. Key Findings: 🩺 Experience: 70% of radiologists have clinical experience with IBD.  📈Disease Activity Scores: More commonly used in university and high-volume hospitals with sMaRIA being the most adopted score. ✅ Agreement: High consensus on key indicators of disease activity and complications. These included: intestinal wall thickness, presence of mucosal ulcers, presence of edema, mucosal enhancement. Achieving transmural healing, defined as a bowel thickness ≤ 3 mm, is a key predictor of better long-term outcomes. 📋Structured Reporting: Only 22.9% use structured MRE reports regularly, and the use of radiological scores is limited, with low confidence in MaRIA/sMaRIA scores. 🏥High-Volume Centers: Facilities with >1000 IBD cases/year typically used a more advanced MRI scanner. 🤝Multidisciplinary Meetings: Involvement is higher in university hospitals (76.1%) compared to public hospitals (30%). Conclusions: While there is a high consensus on transmural healing being a key indicator of better long-term outcomes, the adoption of standardised scores to evaluate, monitor, and treat IBD needs improvement. 🔗's in the comments below! (below, an example of an MR Enterography study) #crohns #ibd #crohnsandcolitis #colitis

👫 540,000 people are living with #Crohns and #Colitis in the UK 🩺 25,000 new diagnoses each year 📆 5.5 years to receive a diagnosis A big day for #CrohnsandColitis awareness! Watch the clip below from the #BBCBreakfast show where Lucy shares her powerful #IBD journey. Followed by Crohn's & Colitis UK talking about how they support patients from first symptoms through their journey. #inflammatoryboweldisease #crohnsandcolitisuk #patientsupport